As of November 10, 2026, Artiva Biotherapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on May 19, 2026 (Form 8-K, May 19, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Artiva Biotherapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Artiva Biotherapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-05-19. Every row below is cited to the filing it comes from, and this page adds each new change as Artiva Biotherapeutics, Inc. files it.
Layoffs on record: about 131 jobs, latest 2026-11-09 (layoff filings and notices).
Also on the record for Artiva Biotherapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G/A, by Venrock Healthcare Capital Partners III, L.P. | 4.2% of the class | 5%+ stakes | Source |
| August 10, 2026 | Stake report, Schedule 13G/A, by Andrew J. Schwab | 4.8% of the class | 5%+ stakes | Source |
| July 23, 2026 | Stake report, Schedule 13D/A, by RA Capital Management, L.P. | 37.9% of the class | 5%+ stakes | Source |
| June 15, 2026 | Stake report, Schedule 13D/A, by RA Capital Management, L.P. | 36.6% of the class | 5%+ stakes | Source |
| May 28, 2026 | Stake report, Schedule 13D/A, by GC Corp | 12.3% of the class | 5%+ stakes | Source |
| May 18, 2026 | Stake report, Schedule 13G, by VIKING GLOBAL INVESTORS LP | 5.4% of the class | 5%+ stakes | Source |
| May 13, 2026 | Stake report, Schedule 13D/A, by RA Capital Management, L.P. | 33.7% of the class | 5%+ stakes | Source |
| July 16, 2025 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 2% of the class | 5%+ stakes | Source |
| July 22, 2024 | IPO filing, Form 424B4 | $12 a share | IPO filings | Source |
| July 15, 2024 | IPO filing, Form S-1/A | $14 to $16 a share | IPO filings | Source |
Selling to them or working with them? See who runs Artiva Biotherapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Artiva Biotherapeutics, Inc. and the records around it.
Artiva Biotherapeutics, Inc. elsewhere on the record
- Layoff notices Nov 2026
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- 5AM Ventures VI, L.P. also filed stake reports on 2 other companies: CAMP4 THERAPEUTICS CORPORATION (Aug 2026), VOR BIOPHARMA INC. (Jul 2025)
- VIKING GLOBAL INVESTORS LP also filed stake reports on 27 other companies: City Therapeutics, Inc. (Oct 2026), MID AMERICA APARTMENT COMMUNITIES INC. (Oct 2026), REGAL REXNORD CORP (Sep 2026)
- Venrock Healthcare Capital Partners III, L.P. also filed stake reports on 34 other companies: Entera Bio Ltd. (Oct 2026), Lycia Therapeutics, Inc. (Oct 2026), Frazier Life Sciences Acquisition Corp. II (Oct 2026)
Watch Artiva Biotherapeutics, Inc.
Get an email when Artiva Biotherapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Artiva Biotherapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Artiva Biotherapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Artiva Biotherapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-05-19 | Reported | not named in the filing | 8-K, 2026-05-19 |
New leaders reset buying decisions — get the Full Report on Artiva Biotherapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Artiva Biotherapeutics, Inc., with the record behind each one.
Find candidates like senior executive at Artiva Biotherapeutics, Inc.Every change, in the filing's words
Reported
(a) Departure of Director On May 18, 2026, Diego Miralles, M.D. resigned as a member of the Board of Directors (the "Board") of Artiva Biotherapeutics, Inc. (the "Company"), effective May 18, 2026, in connection with his appointment as President and Head of Research and Development of the Company as described below.
- Dr. Miralles's resignation was not a result of any dispute or disagreement with the Company.
- In connection with Dr. Miralles's resignation, the size of the Board was reduced from eight members to seven members.
- (b) Departure of Chief Financial Officer On May 18, 2026, Thad Huston and the Company agreed to Mr. Huston's separation from his position as Chief Financial Officer and principal financial and accounting officer of the Company, effective May 22, 2026 (the "Separation Date").
- Mr. Huston's separation was not the result of any dispute or disagreement with the Company.
- The Company plans to conduct a search for Mr. Huston's replacement.
- In connection with Mr. Huston's separation from the Company, he and the Company entered into a separation agreement, dated as of May 18, 2026 (the "Separation Agreement"), pursuant to which Mr. Huston will: (i) receive a cash payment equal to three months of his base salary in effect as of the Separation Date (in the total amount of approximately $135,000), subject to standard payroll deductions and withholdings; and (ii) receive up to nine months of COBRA group health insurance continuation.
- The foregoing severance benefits are conditioned upon Mr. Huston not revoking the Separation Agreement on or within 21 calendar days after the Separation Date.
Tools for this story
Each opens in a new tab, filled in for Artiva Biotherapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.